Literature DB >> 27357735

Circadian variation of metabotropic glutamate receptor 5 availability in the rat brain.

David Elmenhorst1, Kristina Mertens1, Tina Kroll1, Angela Oskamp1, Johannes Ermert2, Eva-Maria Elmenhorst3, Franziska Wedekind1, Simone Beer1, Heinz H Coenen2, Andreas Bauer1.   

Abstract

The metabotrophic subtype 5 glutamate receptor (mGluR5) plays a critical role in synaptic plasticity besides its involvement in numerous neurological disorders, such as depression. As mGluR5 availability in humans is altered in sleep deprivation, we hypothesized that mGluR5 availability underlies a circadian variation. To investigate whether mGluR5 underlies potential circadian changes we measured its density in a randomized fashion at six different daytimes in 11 adult Sprague-Dawley rats. mGluR5 density was quantified by positron emission tomography (PET) using the radioactive ligand [11 C]ABP688. [11 C]ABP688 uptake was quantified in nine regions of interest with a reference tissue model. Significant differences in the binding potential (BPND ) and therefore mGluR5 availability between the different circadian times were found in cortex, cingulate cortex, amygdala, caudate putamen and nucleus accumbens. Further post-hoc statistical analysis (Tukey-Kramer test) of the different time-points revealed significant changes in BPND between 07:00 hours (start of light-on phase) and 15:00 hours (last time-point of the light-on phase) in the caudate putamen. This study shows that mGluR5 availability is increased during the light-on, or sleep phase, of rodents by approximately 10%. Given that altered mGluR5 densities play a role in psychiatric disorders, further investigation is warranted to evaluate their circadian involvement in mood changes in humans.
© 2016 European Sleep Research Society.

Entities:  

Keywords:  central nervous system; chronobiology; multi-linear reference tissue model; neuroreceptor; synapse

Mesh:

Substances:

Year:  2016        PMID: 27357735     DOI: 10.1111/jsr.12432

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  21 in total

Review 1.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

2.  In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB.

Authors:  Christine DeLorenzo; Jean-Dominique Gallezot; John Gardus; Jie Yang; Beata Planeta; Nabeel Nabulsi; R Todd Ogden; David C Labaree; Yiyun H Huang; J John Mann; Fabrizio Gasparini; Xin Lin; Jonathan A Javitch; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

3.  Alterations in sleep, sleep spindle, and EEG power in mGluR5 knockout mice.

Authors:  David D Aguilar; Robert E Strecker; Radhika Basheer; James M McNally
Journal:  J Neurophysiol       Date:  2019-11-20       Impact factor: 2.714

4.  Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET.

Authors:  Sophie E Holmes; Jean-Dominique Gallezot; Margaret T Davis; Nicole DellaGioia; David Matuskey; Nabeel Nabulsi; John H Krystal; Jonathan A Javitch; Christine DeLorenzo; Richard E Carson; Irina Esterlis
Journal:  J Cereb Blood Flow Metab       Date:  2019-11-19       Impact factor: 6.200

5.  Effect of (Z)-isomer content on [11C]ABP688 binding potential in humans.

Authors:  Kelly Smart; Sylvia M L Cox; Alexey Kostikov; Aliaksandr Shalai; Stephanie G Scala; Maria Tippler; Natalia Jaworska; Michel Boivin; Jean R Séguin; Chawki Benkelfat; Marco Leyton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-03       Impact factor: 9.236

6.  Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study.

Authors:  Chadi G Abdallah; Jonas Hannestad; Graeme F Mason; Sophie E Holmes; Nicole DellaGioia; Gerard Sanacora; Lihong Jiang; David Matuskey; Ritvij Satodiya; Fabrizio Gasparini; Xin Lin; Jonathan Javitch; Beata Planeta; Nabeel Nabulsi; Richard E Carson; Irina Esterlis
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-04-06

Review 7.  Metabotropic Glutamatergic Receptor 5 and Stress Disorders: Knowledge Gained From Receptor Imaging Studies.

Authors:  Irina Esterlis; Sophie E Holmes; Priya Sharma; John H Krystal; Christine DeLorenzo
Journal:  Biol Psychiatry       Date:  2017-09-19       Impact factor: 13.382

8.  Dysregulation of Decision Making Related to Metabotropic Glutamate 5, but Not Midbrain D3, Receptor Availability Following Cocaine Self-administration in Rats.

Authors:  Stephanie M Groman; Ansel T Hillmer; Heather Liu; Krista Fowles; Daniel Holden; Evan D Morris; Daeyeol Lee; Jane R Taylor
Journal:  Biol Psychiatry       Date:  2020-06-29       Impact factor: 13.382

Review 9.  Purinergic Signaling in Neuron-Astrocyte Interactions, Circadian Rhythms, and Alcohol Use Disorder.

Authors:  Daniel Lindberg; Lindsey Andres-Beck; Yun-Fang Jia; Seungwoo Kang; Doo-Sup Choi
Journal:  Front Physiol       Date:  2018-02-06       Impact factor: 4.566

10.  Noninvasive Relative Quantification of [11C]ABP688 PET Imaging in Mice Versus an Input Function Measured Over an Arteriovenous Shunt.

Authors:  Jeroen Verhaeghe; Daniele Bertoglio; Lauren Kosten; David Thomae; Marleen Verhoye; Annemie Van Der Linden; Leonie Wyffels; Sigrid Stroobants; John Wityak; Celia Dominguez; Ladislav Mrzljak; Steven Staelens
Journal:  Front Neurol       Date:  2018-06-29       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.